Comparison between drug-coated balloons and drug-eluting stents in very small coronary artery interventions

• Published in: Scientific reports Vol. 12; no. 1; p. 10679
• Main Authors: Tsai, Cheng-Hsuan, Yeh, Chih-Fan, Meng, Shih-Wei, Hung, Chi-Sheng, Lin, Mao-Shin, Huang, Ching-Chang, Chen, Chun-Kai, Huang, Kuo-Ping, Chen, Ying-Hsien, Kao, Hsien-Li
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 23.06.2022; Nature Publishing Group; Nature Portfolio
• Subjects: 692/4019/2773; 692/4019/2776; Acute coronary syndromes; Congestive heart failure; Coronary artery; Drug delivery; Humanities and Social Sciences; Implants; Ischemia; multidisciplinary; Science; Science (multidisciplinary); Stents
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-022-14047-7

The optimal management of very small vessel (reference diameter from 2.0 to 2.25 mm) in percutaneous coronary interventions (PCIs) is controversial. We aimed to compare the efficacy and safety of drug-coated balloons (DCBs) and drug-eluting stents (DESs) for de-novo very small vessel interventions. We conducted a retrospective analysis of consecutive patients who received very small vessel PCI with a DCB or DES between January 2018 and March 2021. The outcome measures were the incidence of ischemia-driven target lesion revascularization (TLR) and major adverse cardiac and cerebrovascular events (MACCEs) within 1 year after PCI. MACCEs were defined as the composite of ischemia-driven TLR, all-cause death, non-fatal acute coronary syndrome, stroke, or heart failure requiring hospitalization. A total of 205 patients undergoing PCI with a DCB or DES were enrolled in this study. The procedural complication rate was 2.5% in the DES group and 1.7% in the DCB group (P = 1.000). After 1-year of follow-up, the cumulative incidence of TLR was 7.2% in the DCB group and 4.9% in the DES group (P = 0.530). The cumulative incidence of MACCEs was 10.6% in the DCB group and 12.7% in the DES group (P = 0.769). Only female gender, acute coronary syndrome on presentation, and dual antiplatelet therapy duration < 3 months were significantly associated with MACCEs at 1 year, but the use of DCB or DES was not. The use of DCBs or DESs in de novo very small vessel intervention was not associated with different outcomes at 1 year.